ReviewExpert opinion on drug metabolism & toxicology2018
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
Review in Expert opinion on drug metabolism & toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 7 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- Pooled it
- Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients withFrontiers in microbiology · 2025Pooled it
- A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients.Frontiers in cardiovascular medicine · 2024Pooled it
- Effects of CYP2C19 genetic polymorphisms on the cure rates ofFrontiers in pharmacology · 2022Pooled it
- Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.Gastroenterology · 2021Pooled it
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Clinical pharmacology and therapeutics · 2021Guideline
- AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.Gastroenterology · 2021Guideline
- Assessment of Pharmacokinetic Interaction and Clinical Efficacy of Clopidogrel Co-administered with Ilaprazole.Clinical pharmacology in drug development · 2026Trial
- Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers.Gut and liver · 2026Trial
- Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.British journal of clinical pharmacology · 2022Trial
- Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.Advances in therapy · 2021Trial
- Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17.PloS one · 2021Trial
- The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori.Medicine · 2020Trial
- Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.Clinical drug investigation · 2019Trial
- Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.Clinical and translational science · 2019Trial
- Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients.BioMed research international · 2018Trial
- One PPI may not fit all-prevalence of CYP2C19 phenotypes in patients with Barrett's esophagus.Surgical endoscopy · 2026Article
- Genetic variations in medical versus surgical patients with GERD: beyond PPIs and fundoplications.Surgical endoscopy · 2026Article
- Maternal PPI therapy during lactation: pantoprazole levels in human milk and possible neonatal implications.European journal of pediatrics · 2026Article
- Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency.Arteriosclerosis, thrombosis, and vascular biology · 2026Observational
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionProton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This variable response among patients is in part due to genotype variability of CYP2C19, the gene encoding the CYP450 (CYP2C19) isoenzyme responsible for PPIs metabolism. Areas covered: This article provides an overview of the pharmacokinetics and mechanism of action of the currently available PPIs, including the magnitude of CYPC19 contribution to their metabolism. Additionally, the role of CYP2C19 genetic variability in the therapeutic effectiveness or outcomes of PPI therapy is highlighted in details, to provide supporting evidence for the potential value of CYP2C19 genotype-guided approaches to PPI drug therapy. Expert opinion: There is a large body of evidence describing the impact of CYP2C19 variability on PPIs and its potential role in individualizing PPI therapy, yet, CYP2C19 pharmacogenetics has not been widely implemented into clinical practice. More data are needed but CYP2C19 genotype-guided dosing of PPIs is likely to become increasingly common and is expected to improve clinical outcomes, and minimize side effects related to PPIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.